Lundbeck
Lundbeck are the UK's leading pharmaceutical company specialising in central nervous system (CNS) disorders. This strategic focus has allowed us to establish strong links with academics, clinicians and organisations with interests in CNS disorders, such as depression and anxiety, schizophrenia, Alzheimer's and Parkinson's disease.
Research has been our foundation for more than 50 years and we are known worldwide for our pioneering work. We plough around 20% of our revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.
Lundbeck's mission is to improve the quality of life for people suffering from psychiatric
and neurological diseases. We believe our complete focus and expertise in this area makes us a potentially important partner in mental health, which is a significant part of the national health agenda. Lundbeck are already successfully contributing to the redesign of care pathways and provision of education for HCPs to improve patient outcomes and help deliver the QIPP agenda.
Lundbeck's mission is to improve the quality of life for people suffering from psychiatric
and neurological diseases. We believe our complete focus and expertise in this area makes us a potentially important partner in mental health, which is a significant part of the national health agenda. Lundbeck are already successfully contributing to the redesign of care pathways and provision of education for HCPs to improve patient outcomes and help deliver the QIPP agenda.
Web:
Follow us on Twitter
